6533b7d2fe1ef96bd125ded0
RESEARCH PRODUCT
IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY
Georg HessC. RusconiT. HenningerDolores CaballeroSeok-goo ChoMarek TrnenyW. ZhouIsabelle Bence-brucklerJenna D. GoldbergMathias Witzens-harigMats JerkemanR. Santucci SilvaWojciech JurczakMartin DreylingCristina JoãoJessica VermeulenFritz OffnerSimon RuleCatherine Thieblemontsubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicinemedicine.diseaseTemsirolimus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisInternal medicineIbrutinibMedicineMantle cell lymphomaOpen labelbusinessPreviously treated030215 immunologymedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2017-06-01 | Hematological Oncology |